tbuckley/cabot-search huggingface dataset:
Myeloid Neoplasm with PDGFRB Translocation, t(1;5)(q21;q33): A Congenital Presentation of An Imatinib Responsive Congenital JMML with Eosinophilia
Authors: Shirley M. Abraham, Mohamed E. Salama, Jeffrey R. Jacobsen, Jeffrey Hancock, Mark Fluchel
Journal: Blood (2010)
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma
Authors: S. Teckie, S. Qi, M. Chelius, S. Lovie, M. Hsu, A. Noy, C. Portlock, J. Yahalom
Journal: Annals of Oncology (2017)

Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and treatment strategy on disease control and survival.We identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumulative incidence of relapse.Median follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%, respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse (all P < 0.05). When compared with stomach, MZL originating in other disease sites (HR > 2.0, P ≤ 0.001), except for thyroid, had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when compared with radiation therapy (P < 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma was 2% (11 patients).Overall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This study supports the use of local therapies to treat stage IE and IIE MZL.
Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).
Authors: Adam D. Cohen, Ping Zhou, Lillian Reich, Hani Hassoun, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Stephen D. Nimer, Raymond L. Comenzo
Journal: Blood (2005)
Effect of raloxifene on human pancreatic adenocarcinoma growth in vitro and in vivo.
Authors: H. Seeliger, N. Seel, P. Camaj, I. Ischenko, K. Jauch, C. J. Bruns
Journal: Journal of Clinical Oncology (2011)

207 Background: The role of estrogen receptor (ER) signaling in pancreatic cancer is unknown. Recently, we demonstated that expression of the isoform ER beta correlates with an adverse prognosis in patients with pancreatic cancer. Here, we show that raloxifene, a specific estrogen receptor modulator (SERM), suppresses in vitro and in vivo tumor growth by interfering with ER beta signaling in human pancreatic adenocarcinoma. Methods: The human pancreatic adenocarcinoma cell line L3.6pl was cultured and exposed to raloxifene in vitro, and cell proliferation was determined by the BrdU assay. To analyze the specificity of raloxifene induced effects, ER knockdown was performed using siRNA specific for ER alpha and ER beta. In an in vivo model of orthotopic tumor xenografts in nude mice, raloxifene was administered daily, and tumor growth was monitored. Expression of ER beta and the proliferation marker Ki-67 were determined by immunohistochemistry. Results: Raloxifene treatment resulted in a potent, dose dependent reduction of proliferation in vitro over a nanomolar dose range. This effect was completely reversed by siRNA knockdown of ER beta, but not ER alpha, indicating an ER isotype specific signaling. In vivo, orthotopic tumor growth, as well as lymph node and liver metastases, was significantly suppressed in raloxifene treated mice. Analogous to the in vitro data, Ki-67 expression in vivo was significantly reduced in raloxifene treated mice, while ER beta expression was not changed in vivo. Conclusions: Inhibition of ER beta signaling by raloxifene results in a potent reduction of human pancreatic adenocarcinoma growth in vitro and in vivo. Treatment with SERMs may be an attractive therapeutic option in subjects expressing the ER beta isotype. No significant financial relationships to disclose.
Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: a multicentre, phase 2 study by the Hellenic Oncology Research Group
Authors: E. Saloustros, I. Boukovinas, K. Kalbakis, P. Katsaounis, A. Ardavanis, L. Vamvakas, K. Papazisis, E. Prinarakis, T. Skaltsi, V. Georgoulias, D. Mavroudis
Journal: Annals of Oncology (2016)
Aid-Mediated Hypermutation of B-Cell Receptors with Subsequent Subclone Selection Define Biological Differences Between IgM-Expressing and Isotype-Switched Follicular Lymphoma
Authors: Florian Scherer, Marlon van der Burgt, Cristina Bertinetti-Lapatki, Szymon Kielbasa, Hendrik Veelken, Marcelo A Navarrete
Journal: Blood (2012)
The Protein C Pathway in Human and Murine Sickle Cell Disease: Alterations in Protein C, Thrombomodulin (TM), and Endothelial Protein C Receptor (EPCR) at Baseline and during Acute Vaso-Occlusion
Authors: Yihe Guo, Teresa Uy, Nancy Wandersee, J. Paul Scott, Hartmut Weiler, Sandra Holzhauer, Dawn Retherford, Thomas Foster, Cheryl Hillery
Journal: Blood (2008)
Multicenter retrospective study on new biomarkers predictive of response to sunitinib in metastatic renal cell carcinoma
Authors: G. Pinotti, E. Bolzacchini, A. Tuzi, T. Tartaro, I. Proserpio, M. Mare, I. Vallini, C. Verusio, C. Rossini, A. Ballerio, M. Bregni, S. Barzaghi, S. Artale, I. Ricci, M. Danova, L. Galli, B. Cecila, N. Mumoli, F. Dentali
Journal: Annals of Oncology (2016)
A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens
Authors: W. Ichikawa, K. Uehara, K. Minamimura, C. Tanaka, Y. Takii, H. Miyauchi, S. Sadahiro, K. Shinozaki, K. Fukumoto, T. Otsuji, T. Kambara, S. Morita, Y. Ando, M. Arai, M. Sugihara, T. Sugiyama, Y. Ohashi, Y. Sakata
Journal: Annals of Oncology (2016)
Phase II study of segmental transcatheter arterial chemoembolization using ethiodized oil mixed with cisplatin powder for unresectable hepatocellular carcinoma.
Authors: H. Anai, T. Tanaka, H. Nishiofuku, S. Sueyoshi, K. Yamamoto, K. Morimoto, M. Inoue, H. Sakaguchi, Y. Inaba, K. Kichikawa
Journal: Journal of Clinical Oncology (2011)

292 Background: Conventional transcatheter arterial chemoembolization (TACE) using with ethiodized oil mixed with epirubicin or doxorubicin hydrochloride mainly has been widely adapted for intermediate-stage hepatocellular carcinoma (HCC). However, cisplatin has stronger effect for HCC than epirubicin and in the recent years cisplatin powder was commercially available in Japan and then we can use cisplatin powder mixed with ethiodized oil for HCC. We conducted a phase II study to assess the safety and efficacy of segmental or subsegmental (Seg/Subseg) TACE using a suspension of cisplatin powder mixed with ethiodized oil for unresectable HCC. Methods: Twenty patients with single-nodule HCC that was not indicated for surgical treatment or local ablation therapy were enrolled in this study. Seg/Subseg-TACE was performed by using a 2-F tip microcatheter at a distal portion of the subsegmental artery supplying the tumor. Subsequently, the feeding artery was embolized with gelatin sponge particles. The suspension was prepared by mixing 100 mg of cisplatin powder with 10 ml of ethiodized oil. Primary endpoint of this phase II trial was 2-year local disease free survival (DFS); secondary endpoints evaluated were the safety, time to progression (TTP), and 2-year overall survival (OS) rate. Results: A total of 20 patients (male 15, female 5; mean age 72.4, range 62-83; Child Pugh's A 20) were treated single nodule HCC with Seg/subseg TACE. Median tumor size was 2.6cm (range1.2-5.0cm). The 2-year local DFS was 63.2 %. The following grade 3 or 4 toxicities were observed: platelets reduction 5%, aspartate transaminase elevation 55%, alanine transaminase elevation 40% and alkaline phosphatase elevation 5%. The median TTP was 17.6 months (95%CI, 5.25 to 29.9) and the 2-year OS rate was 94.7%. Conclusions: This phase II study demonstrates that segmental or subsegmental transcatheter arterial chemoembolization using a suspension of cisplatin powder mixed with ethiodized oil is well tolerable, and may achieve significant local tumor control and prolong survival. Further clinical trials are warranted. No significant financial relationships to disclose.
Role of TLR4 In Acute Gvhd After Allogenetic Hematopoietic Stem Cell Transplantation
Authors: Yi Zhao, Qiuyan Liu, Donghua He, Lijuan Wang, Jun Tian, Yang Yang, Peilin Lu, Hanying Bao, Yi Li, Yuanyuan Zheng, Xuetao Cao, Zhen Cai
Journal: Blood (2010)
Suboptimal Busulphan Exposure Is Associated with Mixed Hematopoietic Chimerism, a Risk Factor for Rejection in Bone Marrow Transplantation for Homozygous beta Thalassemia.
Authors: J. David Dennison, Shoaib Al Zadjali, Melanie Tauro, Salam Al Kindi, S. Muralitharan, Krishnaratnam Kanan, Shahina Daar, Anil Pathare, Marie-Helene Quernin, Evelyne Jacqz-Aigrain, R. Krishnamoorthy, Shyam Sundar Ganguly
Journal: Blood (2004)
Weekly cisplatin, leucovorin and 5Fluorouracile (PFL) as first line chemotherapy in selected patients with advanced gastric cancer
Authors: M. Squadroni, F. Brena, E. Cerchiaro, M. Bonomi, M.G. Sauta, C. Ripa, G. Ceresoli, P. Salvini, G. Beretta
Journal: Annals of Oncology (2016)
T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10
Authors: Rick Kapur, Michael Kim, Rukhsana Aslam, Mark J. McVey, Arata Tabuchi, Alice Luo, Jonathan Liu, Yuan Li, Shanjeevan Shanmugabhavananthan, Edwin R. Speck, Anne Zufferey, George Yousef, Haibo Zhang, Matthew T. Rondina, Andrew S. Weyrich, Leendert Porcelijn, Wolfgang M. Kuebler, Arthur S. Slutsky, John W. Semple
Journal: Blood (2017)
Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis
Authors: F. Poggio, M. Ceppi, M. Lambertini, P. Bruzzi, D. Ugolini, C. Bighin, A. Levaggi, S. Giraudi, A. D'alonzo, M. Vaglica, E. Blondeaux, B. Conte, M.R. Sertoli, P. Pronzato
Journal: Annals of Oncology (2016)
FLIPLong(L) and FLIPShort(S) Overexpression in the Human Myeloid Leukemia Cell Line ML-1 and Its Role in TRAIL [Tumor Necrosis Factor(TNF)-Related Apoptosis-Inducing Ligand] and TNFa Induced Apoptosis.
Authors: Sudeshna Seal, Daniella B. Kerbauy, Vladimir Lesnikov, Nissa Abbasi-Shafer, H. Joachim Deeg
Journal: Blood (2005)
WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERThigh Prostate Cancer Stem Cells
Authors: Kai Zhang, Yanjing Guo, Xue Wang, Huifang Zhao, Zhongzhong Ji, Chaping Cheng, Li Li, Yuxiang Fang, Dawei Xu, Helen He Zhu, Wei-Qiang Gao
Journal: Cancer Research (2017)

Cancer stem-like cells (CSC) drive cancer progression and recurrence. Self-renewal expansion of CSC is achieved through symmetric cell division, yet how external stimuli affect intracellular regulatory programs of CSC division modes and stemness remains obscure. Here, we report that the hTERThigh prostate cancer cells exhibit CSC properties, including a stem cell-associated gene expression signature, long-term tumor-propagating capacity and epithelial-to-mesenchymal transition. In promoting the self-renewal symmetric division of hTERThigh prostate cancer cells, WNT3a dramatically decreased the ratio of hTERThigh prostate cancer cells undergoing asymmetric division. Increased WNT/β-catenin signal activation was also detected in hTERThigh prostate cancer cells. hTERT-mediated CSC properties were at least partially dependent on β-catenin. These findings provide novel cellular and molecular mechanisms for the self-renewal of CSC orchestrated by tumor microenvironmental stimuli and intracellular signals. Cancer Res; 77(9); 2534-47. ©2017 AACR.
OS4.1 Detection of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for diagnosing IDH1 mutant glioma
Authors: K. Tanaka, H. Nagashima, T. Sasayama, N. Satoh, Y. Irino, E. Kohmura
Journal: Neuro-Oncology (2016)

Mutations in the isocitrate dehydrogenase 1 (IDH1) gene are frequently observed in low-grade glioma and secondary glioblastoma and strongly associated with the accumulation of 2-hydroxyglutarate (2HG), which is a valuable diagnostic and prognostic biomarker of IDH1 mutant glioma. However, conventional magnetic resonance spectroscopy (MRS)-based noninvasive detection of 2HG is still challenging. Therefore, reliable measurements of other metabolites with conventional MRS are necessary to develop a noninvasive detection of IDH1 mutant glioma. Forty-seven patients with glioma underwent conventional single voxel short echo time MRS prior to surgery. A stereotactic navigation-guided operation was performed to resect tumor tissues in the center of the MRS voxel. MRS-based measurements of metabolites were validated with gas chromatography-mass spectrometry (GC-MS). We also conducted integrated analyses of glioma cell lines and clinical samples to examine the other metabolite levels and molecular findings in IDH1 mutant gliomas. Of the 47 patients enrolled in this study, 18 (38.3%) had histologically verified IDH1 mutation. A metabolomic analysis demonstrated higher levels of 2HG in IDH1 mutant glioma cells and surgical tissues. Interestingly, glutamate levels were significantly decreased in IDH1 mutant gliomas. Through an analysis of metabolic enzyme genes in glutamate pathways, the expressions of branched-chain amino acid transaminase 1 were reduced and glutamate dehydrogenase levels were elevated in IDH1 mutant gliomas. Conventional MRS detection of glutamate and 2HG resulted in high sensitivity and specificity (72% and 96%, respectively) for IDH1 mutant glioma. Glutamate metabolism is altered by IDH1 mutations. The combined detection of glutamate and 2HG by MRS may be useful in the clinical management of IDH1 mutant glioma patients.
TMIC-01. MOLECULAR AND CLINICAL CHARACTERIZATION OF PD-L1 EXPRESSION AT TRANSCRIPTIONAL LEVEL VIA 976 SAMPLES OF BRAIN GLIOMA
Authors: Zheng Wang
Journal: Neuro-Oncology (2016)

PD-L1 have been widely reported as immune check points in a range of malignancies as well as some immune-originated diseases. In glioma, the role of PD-L1 remains unclear. We aimed at investigating its role at transcriptome level and relationship with clinical practice. In total, 976 glioma samples with transcriptome data, including 301 microarray data from Chinese Glioma Genome Atlas (CGGA project) and 675 RNAseq data from TCGA project, were enrolled into our study. Clinical and IDH mutation data were also available. R language was used as the main tool for statistical analysis and graphical work. PD-L1 expression was found to be positively correlated with WHO grade of glioma. PD-L1 seemed to express more in mesenchymal subtype according to TCGA transcriptional classification scheme and may contribute as a potential marker for mesenchymal subtype in glioblastoma. Pearson correlation test indicated that PD-L1 showed robust correlation with PD1, PD-L2 and CD80 in CGGA dataset. Subsequent gene ontology analysis based on significantly correlated genes of PD-L1 revealed that PD-L1 seemed to be profoundly associated with T cell activation. To further investigate the relationship between PD-L1 expression and immune response, we selected a series of immune signatures, which were then transformed into metagenes, and found that PD-L1 expression was particularly paralleled with T-cells and macrophages related immune response instead of B cell linage related immune response. In line with the corresponding biological process, PD-L1 exhibited predictive value for glioma patients: higher PD-L1 indicated significantly shorter survival, especially in glioblastoma. PD-L1 is upregulated in glioblastoma, and is synergistic with other check point members. Moreover, PD-L1 is significantly associated with T-cell activation and macrophage related immune response and predicts much worse survival for patients, warranting clinical trials of PD1/PD-L1 checkpoint inhibitors for potential glioma treatment.
Oral absorption of diflomotecan, a new E-ring modified camptothecin analogue, administered as soft-gel capsule
Authors: T. Lesimple, J. Egreteau, P. Fumoleau, M. Campone, A. Lortholary, P. Soulié, C. Peraire, P. Principe, B. Le Mosquet, C. Granger
Journal: Journal of Clinical Oncology (2004)

2045 Background: The E-ring modified camptothecin analogue diflomotecan (BN80915, Ipsen Group) is a new topoisomerase I inhibitor. Its clinical development includes five phase I studies using the iv and oral routes of administration. The trial reported here is in progress to explore the safety, PK and PK/PD haematotoxicity correlation of diflomotecan delivered as a soft-gel capsule, daily for 5 days, every 3 weeks. Methods: To assess the absolute bioavailability, patients received an iv administration at the same daily dose 2 weeks prior the soft-gel capsules. To date, five daily dose levels have been explored (0.15, 0.20, 0.25, 0.30 and 0.35 mg) and 17 patients have been treated with diflomotecan. Results: Three patients have been included at each dose level, except at the RD (0.30 mg), the cohort being extended to six patients. The MTD has been reached at 0.35 mg since 2 out of 3 patients experienced DLTs (neutropenia G4 > 7 days and neutropenia-induced cycle delay). Mean exposure at 0.35 mg was 10.1±4.6 (D1) and 10.5±3.6 ng·hr/ml-1 (D5). Previous mean exposure values obtained with the oral solution were of similar order of magnitude (18.03 ± 11.88, D1, and 11.26 ± 6.15 ng·h·ml-1, D5). The results obtained using the soft-gel capsules are in agreement with the data obtained previously using the oral solution (Gelderblom et al, Clin Cancer Res 9, 2003) as reported in the attached table. Conclusions: Overall, the data confirm the good oral bioavailability of diflomotecan administered as soft-gel capsule and support further clinical evaluation of this new formulation. No significant financial relationships to disclose.
Risk factor analysis of skeletal related events in gastric cancer patients with bone metastasis
Authors: Toshihiko Matsumoto, Kaori Hino, Akio Nakasya, Norifumi Nishide, Kazuhiro Uesugi, Akinori Asagi, Takeshi Kajiwara, Tomohiro Nishina, Shinichiro Hori, Seijin Nadano, Hiroshi Ishii
Journal: Annals of Oncology (2016)
Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
Authors: B. Besse, F. Barlesi, M. Ceccarelli, G.Y. Chao, B. Frimodt-Moller, M. Gil, J. Vansteenkiste
Journal: Annals of Oncology (2016)
Sphingosine Kinases (SK): Key Molecules Associated with the Activation, Proliferation and Ibrutinib-Induced Cell Death of Chronic Lympocytic Leukemia Cells
Authors: Maria Belen Almejun, Mercedes Borge, Ana Colado, Enrique Podaza, Denise Risnik, Carlos Daniel De Brasi, Pablo Oppezzo, Maria Cabrejo, Horacio Fernandez Grecco, Raimundo F. Bezares, Santiago C Cranco, Ruben A. Burgos, Julio Cesar Sanchez Avalos, Mirta N. Giordano, Romina Gamberale
Journal: Blood (2015)
Acetaminophen in Pregnancy and Adverse Childhood Neurodevelopment
Authors: Margaret Olivia Little, Marisha N. Wickremsinhe, Anne Drapkin Lyerly
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma
Authors: J. Kang, K.-P. Kim, C. Yoo, J.-L. Lee, B.-Y. Ryoo, H.-M. Chang, S.S. Lee, D.H. Park, T.J. Song, D.W. Seo, S.K. Lee, M.-H. Kim, D.W. Hwang, K.B. Song, J.H. Lee, S.C. Kim
Journal: Annals of Oncology (2016)
High Levels of High Sensitivity-C Reactive Protein (hs-CRP) Are Associated with Older Age, Chromosomal Abnormalities and JAK2V617F Mutation with High Allele Burden in Primary Myelofibrosis (PMF)
Authors: Giovanni Barosi, Margherita Massa, Gabriela Fois, Rita Campanelli, Elisa Bonetti, Valentina Poletto, Laura Villani, Paolo Catarsi, Vittorio Rosti
Journal: Blood (2016)
Proteinated Elemental Selenium Potentiates Anti-Tumor Effect of Ionizing Radiation and Chemotherapeutic Agents but Is Only Minimally Affected by Drug Resistance Mechanisms.
Authors: Ichiro Tsujino, Kiyoko Miyagi, Reynee W. Sampson, Wolfgang H.H. Gunther, Marianne Krieg, Fritz Sieber
Journal: Blood (2004)
SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models
Authors: S. Napolitano, V. Belli, M.D. Castellone, A. Parascandolo, E. Martinelli, G. Martini, C. Cardone, F. Morgillo, M. Orditura, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2016)